Opus Point Partners Management LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 43.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,506 shares of the life sciences company’s stock after selling 4,211 shares during the quarter. Illumina comprises about 2.6% of Opus Point Partners Management LLC’s investment portfolio, making the stock its 11th largest holding. Opus Point Partners Management LLC’s holdings in Illumina were worth $1,302,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in ILMN. Jackson Square Partners LLC lifted its position in shares of Illumina by 263.0% during the fourth quarter. Jackson Square Partners LLC now owns 1,034,454 shares of the life sciences company’s stock valued at $226,017,000 after buying an additional 749,468 shares during the last quarter. Federated Investors Inc. PA lifted its position in shares of Illumina by 3,088.6% during the first quarter. Federated Investors Inc. PA now owns 492,287 shares of the life sciences company’s stock valued at $116,387,000 after buying an additional 476,848 shares during the last quarter. Prudential Financial Inc. lifted its position in shares of Illumina by 75.9% during the first quarter. Prudential Financial Inc. now owns 762,186 shares of the life sciences company’s stock valued at $180,196,000 after buying an additional 328,886 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Illumina during the first quarter valued at about $61,394,000. Finally, Carillon Tower Advisers Inc. purchased a new stake in shares of Illumina during the fourth quarter valued at about $33,752,000. 90.54% of the stock is owned by institutional investors and hedge funds.
Several research firms have commented on ILMN. Citigroup increased their price target on shares of Illumina from $275.00 to $330.00 and gave the company a “buy” rating in a research report on Monday, June 25th. Morgan Stanley increased their price objective on shares of Illumina from $180.00 to $195.00 and gave the company an “underweight” rating in a research report on Thursday, May 31st. Canaccord Genuity increased their price objective on shares of Illumina from $270.00 to $290.00 and gave the company a “top pick” rating in a research report on Tuesday, May 29th. Barclays raised shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 price objective for the company in a research report on Monday, May 7th. Finally, ValuEngine lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Thursday, April 26th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the stock. Illumina presently has an average rating of “Buy” and an average price target of $256.42.
In other news, Director Robert S. Epstein sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $288.45, for a total transaction of $144,225.00. Following the sale, the director now owns 6,639 shares of the company’s stock, valued at approximately $1,915,019.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 116 shares of the firm’s stock in a transaction that occurred on Tuesday, April 3rd. The stock was sold at an average price of $230.91, for a total transaction of $26,785.56. Following the sale, the senior vice president now directly owns 7,875 shares in the company, valued at approximately $1,818,416.25. The disclosure for this sale can be found here. Insiders have sold a total of 39,271 shares of company stock worth $10,483,503 in the last ninety days. Corporate insiders own 0.54% of the company’s stock.
Shares of Illumina opened at $279.29 on Friday, Marketbeat.com reports. Illumina, Inc. has a twelve month low of $167.98 and a twelve month high of $293.15. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.41 and a current ratio of 2.71. The company has a market capitalization of $40.50 billion, a P/E ratio of 69.82, a price-to-earnings-growth ratio of 2.94 and a beta of 0.88.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The company had revenue of $782.00 million for the quarter, compared to the consensus estimate of $744.30 million. During the same quarter in the prior year, the company earned $0.64 EPS. Illumina’s quarterly revenue was up 30.8% on a year-over-year basis. analysts forecast that Illumina, Inc. will post 4.86 earnings per share for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.